AU2002230727A1 - Indazolyl-substituted pyrroline compounds as kinase inhibitors - Google Patents

Indazolyl-substituted pyrroline compounds as kinase inhibitors

Info

Publication number: AU2002230727A1
Authority: AU; Australia
Prior art keywords: alkyl; group; halo; aryl; hydrogen
Prior art date: 2000-12-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002230727A

Other languages

English (en)

Inventor

Bruce Conway

Leonard R. Hecker

Bruce Maryanoff

David F Mccomsey

Kimberly White

Hong Ye

Han-Cheng Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceuticals Inc

Original Assignee

Ortho McNeil Pharmaceutical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-08

Filing date

2001-12-06

Publication date

2002-06-18

2001-12-06 Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc

2002-06-18 Publication of AU2002230727A1 publication Critical patent/AU2002230727A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

AU2002230727A 2000-12-08 2001-12-06 Indazolyl-substituted pyrroline compounds as kinase inhibitors Abandoned AU2002230727A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25416600P	2000-12-08	2000-12-08
US60/254,166		2000-12-08
PCT/US2001/047689 WO2002046183A2 (en)	2000-12-08	2001-12-06	Indazolyl-substituted pyrroline compounds as kinase inhibitors

Publications (1)

Publication Number	Publication Date
AU2002230727A1 true AU2002230727A1 (en)	2002-06-18

Family

ID=22963185

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002230727A Abandoned AU2002230727A1 (en)	2000-12-08	2001-12-06	Indazolyl-substituted pyrroline compounds as kinase inhibitors

Country Status (26)

Country	Link
US (4)	US6849643B2 (pt)
EP (1)	EP1362047B1 (pt)
JP (1)	JP2004515499A (pt)
KR (1)	KR20040016828A (pt)
CN (1)	CN1230434C (pt)
AT (1)	ATE326464T1 (pt)
AU (1)	AU2002230727A1 (pt)
BR (1)	BR0116468A (pt)
CA (1)	CA2431166A1 (pt)
CY (1)	CY1106125T1 (pt)
CZ (1)	CZ20031594A3 (pt)
DE (1)	DE60119790T2 (pt)
DK (1)	DK1362047T3 (pt)
ES (1)	ES2263681T3 (pt)
HK (1)	HK1057370A1 (pt)
HU (1)	HUP0303855A3 (pt)
IL (1)	IL156339A0 (pt)
MX (1)	MXPA03005140A (pt)
NO (1)	NO20032625L (pt)
NZ (1)	NZ526356A (pt)
PL (1)	PL362576A1 (pt)
PT (1)	PT1362047E (pt)
RU (1)	RU2003117078A (pt)
WO (1)	WO2002046183A2 (pt)
YU (1)	YU46603A (pt)
ZA (1)	ZA200305239B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1362047B1 (en) *	2000-12-08	2006-05-17	Ortho-McNeil Pharmaceutical, Inc.	Indazolyl-substituted pyrroline compounds as kinase inhibitors
MXPA04004026A (es) *	2001-10-29	2004-07-08	Nektar Therapeutics Al Corp	Conjugados polimericos de inhibidores de la proteina quinasa c.
EP1483265B1 (en)	2002-03-05	2006-11-22	Eli Lilly And Company	Purine derivatives as kinase inhibitors
ATE368657T1 (de)	2002-03-08	2007-08-15	Lilly Co Eli	Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
US7125878B2 (en) *	2002-05-08	2006-10-24	Janssen Pharmaceutica	Substituted pyrroline kinase inhibitors
CA2488798A1 (en) *	2002-06-05	2003-12-18	Janssen Pharmaceutica N.V.	Substituted pyrrolines as kinase inhibitors
US7488826B2 (en) *	2003-03-27	2009-02-10	Janssen Pharmaceutica N.V.	Substituted pyrroline kinase inhibitors
CN1832940A (zh) *	2003-06-13	2006-09-13	詹森药业有限公司	用作激酶抑制剂的取代的吲唑基(吲哚基)马来酰亚胺衍生物
US7226941B2 (en) *	2003-06-30	2007-06-05	Hif Bio, Inc.	Compound for treating angiogenesis
CN1950502B (zh) *	2003-09-19	2011-07-27	儿童医院医学中心	心肌收缩性和心力衰竭倾向的调节
JP4794446B2 (ja) *	2003-09-23	2011-10-19	メルク・シャープ・エンド・ドーム・コーポレイション	イソキノリン系カリウムチャンネル阻害薬
EP1827585A4 (en) *	2004-11-23	2010-01-06	Internat Bio Therapeutic Res I	METHOD FOR DISPENSING THERAPEUTIC METALIONS, ALLOYS AND SALTS
US8017395B2 (en)	2004-12-17	2011-09-13	Lifescan, Inc.	Seeding cells on porous supports
SE0500055D0 (sv)	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
SE0500058D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 5
EP1838686A4 (en)	2005-01-10	2010-02-24	Astrazeneca Ab	ISOTHIAZOL-3 (2H) -ONE 1,1-DIOXIDE DERIVATIVES AS LIVER X-RECEPTOR MODULATORS
CA2601766A1 (en) *	2005-03-17	2006-09-28	Novartis Ag	N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
SI1888123T1 (sl)	2005-06-08	2013-04-30	Janssen Biotech, Inc.	Celična terapija za okularno degeneracijo
WO2007008514A2 (en) *	2005-07-07	2007-01-18	Georgetown University	Inhibitors of glycogen synthase kinase 3
CA2624378A1 (en) *	2005-09-29	2007-04-12	Janssen Pharmaceutica N.V.	Macroheterocylic compounds as kinase inhibitors
US8741643B2 (en)	2006-04-28	2014-06-03	Lifescan, Inc.	Differentiation of pluripotent stem cells to definitive endoderm lineage
US7741290B2 (en)	2006-06-01	2010-06-22	The Board of Trustee of The Leland Stanford Juinior University	Method of preventing progression of hypertension-induced heart failure with PKC peptides
ES2446269T3 (es)	2006-12-19	2014-03-06	The Board Of Trustees Of The University Of Illinois	3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
CA2676906A1 (en) *	2007-02-12	2008-08-21	Intermune, Inc.	Novel inhibitors hepatitis c virus replication
US9080145B2 (en)	2007-07-01	2015-07-14	Lifescan Corporation	Single pluripotent stem cell culture
CN101952415B (zh)	2007-07-31	2017-06-27	生命扫描有限公司	人胚胎干细胞的分化
CA2706560C (en)	2007-11-27	2017-02-28	Lifescan, Inc.	Differentiation of human embryonic stem cells to pancreatic cells
KR101731474B1 (ko)	2008-02-21	2017-05-11	얀센 바이오테크 인코포레이티드	세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
US8623648B2 (en) *	2008-04-24	2014-01-07	Janssen Biotech, Inc.	Treatment of pluripotent cells
JP5734183B2 (ja)	2008-06-30	2015-06-17	ヤンセンバイオテツク，インコーポレーテツド	多能性幹細胞の分化
KR102025158B1 (ko)	2008-10-31	2019-09-25	얀센 바이오테크 인코포레이티드	인간 배아 줄기 세포의 췌장 내분비 계통으로의 분화
BRPI0919885A2 (pt)	2008-10-31	2015-08-11	Centocor Ortho Biotech Inc	Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática
KR101687344B1 (ko)	2008-11-20	2016-12-16	얀센 바이오테크 인코포레이티드	평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
WO2010059775A1 (en)	2008-11-20	2010-05-27	Centocor Ortho Biotech Inc.	Pluripotent stem cell culture on micro-carriers
CA2768720C (en)	2009-07-20	2018-12-18	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells
AU2010276440B2 (en)	2009-07-20	2014-07-03	Janssen Biotech Inc.	Differentiation of human embryonic stem cells
BR112012001480A2 (pt)	2009-07-20	2015-09-01	Janssen Biotech Inc	Diferenciação de células-tronco embriônicas humanas
RU2664864C1 (ru)	2009-12-23	2018-08-23	Янссен Байотек, Инк.	Способы увеличения экспрессии ngn3 и nkx6.1 в эндокринных клетках поджелудочной железы
BR112012017761A2 (pt)	2009-12-23	2015-09-15	Centocor Ortho Biotech Inc	diferenciação das células-tronco embrionárias humanas
CN107189979B (zh)	2010-03-01	2021-05-04	詹森生物科技公司	纯化衍生自多能干细胞的细胞的方法
SG185511A1 (en)	2010-05-12	2012-12-28	Centocor Ortho Biotech Inc	Differentiation of human embryonic stem cells
MX2012013197A (es)	2010-05-12	2013-04-03	Abbvie Inc	Inhibidores de indazol de cinasa.
CN103154239B (zh)	2010-08-31	2018-05-15	詹森生物科技公司	人胚胎干细胞的分化
EP2611907B1 (en)	2010-08-31	2016-05-04	Janssen Biotech, Inc.	Differentiation of pluripotent stem cells
WO2012030538A2 (en)	2010-08-31	2012-03-08	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells
JP6441080B2 (ja)	2011-12-22	2018-12-19	ヤンセンバイオテツク，インコーポレーテツド	単一ホルモンのインスリン陽性細胞へのヒト胚性幹細胞の分化
EP2823037A4 (en)	2012-03-07	2015-09-16	Janssen Biotech Inc	DEFINED MEDIA FOR THE EXPANSION AND CARE OF PLURIPOTENTAL STEM CELLS
EP2859091B1 (en)	2012-06-08	2018-08-29	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells into pancreatic endocrine cells
EP2928466B1 (en)	2012-12-10	2020-10-28	Centogene GmbH	Use of maleimide derivatives for preventing and treating leukemia
US10370644B2 (en)	2012-12-31	2019-08-06	Janssen Biotech, Inc.	Method for making human pluripotent suspension cultures and cells derived therefrom
CN105073979B (zh)	2012-12-31	2020-03-06	詹森生物科技公司	使用hb9调节子使人胚胎干细胞分化为胰腺内分泌细胞的方法
SG11201505119UA (en)	2012-12-31	2015-07-30	Janssen Biotech Inc	Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
RU2658488C2 (ru)	2012-12-31	2018-06-21	Янссен Байотек, Инк.	Способ получения клеток, экспрессирующих маркеры, характерные для панкреатических эндокринных клеток
SG10201810739VA (en)	2014-05-16	2019-01-30	Janssen Biotech Inc	Use of small molecules to enhance mafa expression in pancreatic endocrine cells
GB201509885D0 (en) *	2015-06-08	2015-07-22	Ucb Biopharma Sprl	Therapeutic agents
MA45479A (fr)	2016-04-14	2019-02-20	Janssen Biotech Inc	Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
US10383881B2 (en)	2016-12-30	2019-08-20	Frequency Therapeutics, Inc.	1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
CN110392686A (zh)	2016-12-30	2019-10-29	频率治疗公司	1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
EP3860998B1 (en)	2018-10-05	2023-12-27	Annapurna Bio Inc.	Compounds and compositions for treating conditions associated with apj receptor activity
US20220133740A1 (en)	2019-02-08	2022-05-05	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders
ES2986788T3 (es)	2020-02-07	2024-11-12	Gasherbrum Bio Inc	Agonistas heterocíclicos de GLP-1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ280738B6 (cs) *	1988-02-10	1996-04-17	F. Hoffmann - La Roche And Co., Aktiengesellschaft	Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) *	1989-02-23	1989-04-05	Hoffmann La Roche	Substituted pyrroles
MC2096A1 (fr)	1989-02-23	1991-02-15	Hoffmann La Roche	Pyrroles substitues
DE4005970A1 (de)	1990-02-26	1991-08-29	Boehringer Mannheim Gmbh	Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de)	1990-02-26	1991-08-29	Boehringer Mannheim Gmbh	Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5624949A (en)	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
DK0817627T3 (da)	1993-12-23	2005-06-06	Lilly Co Eli	Inhibitorer af proteinkinase C
SE9603283D0 (sv)	1996-09-10	1996-09-10	Astra Ab	New compounds
EP1057484A4 (en)	1998-02-23	2002-11-20	Sagami Chem Res	INHIBITORS OF CELL DEATH
KR20010085305A (ko)	1998-07-30	2001-09-07	미즈노 마사루	이치환된 말레이미드 화합물 및 그의 의약 용도
ATE284387T1 (de) *	1998-10-08	2004-12-15	Smithkline Beecham Plc	3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
EP1362047B1 (en) *	2000-12-08	2006-05-17	Ortho-McNeil Pharmaceutical, Inc.	Indazolyl-substituted pyrroline compounds as kinase inhibitors
US7125878B2 (en)	2002-05-08	2006-10-24	Janssen Pharmaceutica	Substituted pyrroline kinase inhibitors
CA2488798A1 (en)	2002-06-05	2003-12-18	Janssen Pharmaceutica N.V.	Substituted pyrrolines as kinase inhibitors
KR20050008787A (ko)	2002-06-05	2005-01-21	얀센 파마슈티카 엔.브이.	키나제 저해제로서의 비스인돌릴-말레이미드 유도체
US7488826B2 (en)	2003-03-27	2009-02-10	Janssen Pharmaceutica N.V.	Substituted pyrroline kinase inhibitors
CN1832940A (zh) *	2003-06-13	2006-09-13	詹森药业有限公司	用作激酶抑制剂的取代的吲唑基(吲哚基)马来酰亚胺衍生物

2001
- 2001-12-06 EP EP01990971A patent/EP1362047B1/en not_active Expired - Lifetime
- 2001-12-06 CZ CZ20031594A patent/CZ20031594A3/cs unknown
- 2001-12-06 ES ES01990971T patent/ES2263681T3/es not_active Expired - Lifetime
- 2001-12-06 DE DE60119790T patent/DE60119790T2/de not_active Expired - Fee Related
- 2001-12-06 CN CNB018225675A patent/CN1230434C/zh not_active Expired - Fee Related
- 2001-12-06 CA CA002431166A patent/CA2431166A1/en not_active Abandoned
- 2001-12-06 KR KR10-2003-7007710A patent/KR20040016828A/ko not_active Application Discontinuation
- 2001-12-06 RU RU2003117078/04A patent/RU2003117078A/ru not_active Application Discontinuation
- 2001-12-06 AU AU2002230727A patent/AU2002230727A1/en not_active Abandoned
- 2001-12-06 PT PT01990971T patent/PT1362047E/pt unknown
- 2001-12-06 IL IL15633901A patent/IL156339A0/xx unknown
- 2001-12-06 YU YU46603A patent/YU46603A/sh unknown
- 2001-12-06 MX MXPA03005140A patent/MXPA03005140A/es active IP Right Grant
- 2001-12-06 US US10/013,181 patent/US6849643B2/en not_active Expired - Lifetime
- 2001-12-06 BR BR0116468-6A patent/BR0116468A/pt not_active IP Right Cessation
- 2001-12-06 WO PCT/US2001/047689 patent/WO2002046183A2/en active IP Right Grant
- 2001-12-06 AT AT01990971T patent/ATE326464T1/de not_active IP Right Cessation
- 2001-12-06 PL PL01362576A patent/PL362576A1/xx not_active Application Discontinuation
- 2001-12-06 JP JP2002547921A patent/JP2004515499A/ja not_active Ceased
- 2001-12-06 HU HU0303855A patent/HUP0303855A3/hu unknown
- 2001-12-06 NZ NZ526356A patent/NZ526356A/xx unknown
- 2001-12-06 DK DK01990971T patent/DK1362047T3/da active
2003
- 2003-06-10 NO NO20032625A patent/NO20032625L/no not_active Application Discontinuation
- 2003-07-07 ZA ZA200305239A patent/ZA200305239B/en unknown
2004
- 2004-01-12 HK HK04100221A patent/HK1057370A1/xx not_active IP Right Cessation
- 2004-07-06 US US10/885,373 patent/US7304060B2/en not_active Expired - Fee Related
- 2004-08-02 US US10/909,537 patent/US7329657B2/en not_active Expired - Fee Related
2006
- 2006-07-21 CY CY20061101017T patent/CY1106125T1/el unknown
2007
- 2007-12-13 US US12/001,805 patent/US7855203B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ZA200305239B (en)	2004-10-07
MXPA03005140A (es)	2004-10-15
US20080096949A1 (en)	2008-04-24
CA2431166A1 (en)	2002-06-13
CZ20031594A3 (cs)	2004-06-16
DK1362047T3 (da)	2006-09-04
PT1362047E (pt)	2006-09-29
YU46603A (sh)	2006-05-25
EP1362047A2 (en)	2003-11-19
HUP0303855A2 (hu)	2004-03-01
CY1106125T1 (el)	2011-06-08
HK1057370A1 (en)	2004-04-02
NZ526356A (en)	2005-02-25
US7329657B2 (en)	2008-02-12
ATE326464T1 (de)	2006-06-15
IL156339A0 (en)	2004-01-04
HUP0303855A3 (en)	2005-04-28
NO20032625L (no)	2003-08-05
RU2003117078A (ru)	2004-12-10
KR20040016828A (ko)	2004-02-25
US7855203B2 (en)	2010-12-21
DE60119790T2 (de)	2007-01-25
NO20032625D0 (no)	2003-06-10
WO2002046183A2 (en)	2002-06-13
US20040259928A1 (en)	2004-12-23
ES2263681T3 (es)	2006-12-16
EP1362047B1 (en)	2006-05-17
JP2004515499A (ja)	2004-05-27
DE60119790D1 (de)	2006-06-22
US6849643B2 (en)	2005-02-01
WO2002046183A3 (en)	2002-09-06
US7304060B2 (en)	2007-12-04
PL362576A1 (en)	2004-11-02
US20050004202A1 (en)	2005-01-06
BR0116468A (pt)	2004-06-29
CN1230434C (zh)	2005-12-07
US20030055097A1 (en)	2003-03-20
CN1489586A (zh)	2004-04-14

Publication	Publication Date	Title
EP1362047B1 (en)	2006-05-17	Indazolyl-substituted pyrroline compounds as kinase inhibitors
US7759380B2 (en)	2010-07-20	Substituted pyrrolines as kinase inhibitors
US6987110B2 (en)	2006-01-17	Substituted pyrrolines as kinase inhibitors
EP1654255B1 (en)	2008-08-27	Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
US20040006095A1 (en)	2004-01-08	Substituted pyrroline kinase inhibitors
WO2004094422A1 (en)	2004-11-04	Substituted pyrroline kinase inhibitors